Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium

1 Feb 2019

Abstract excerpt

Pyrvinium was identified as the first small molecule inhibitor of the androgen receptor (AR) DNA-binding domain (DBD). It was also among the first small molecules shown to directly inhibit the activity of AR splice variants (ARVs), which has important clinical implications in the treatment of castration-resistant prostate cancer. Important questions about pyrvinium's mechanism of action remain. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hormonal and reproductive studies
Share to Mass Spectrometry Techniques and Applications
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30873507
DOI: 10.1021/acsomega.8b03205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor PyrviniumPMID 30873507Read ↗

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin InteractionsSemantic proximity Read ↗

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.Semantic proximity Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.Semantic proximity Read ↗

Discovery of drugs that directly target the intrinsically disordered region of the androgen receptorSemantic proximity Read ↗

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domainSemantic proximity Read ↗

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive reviewSemantic proximity Read ↗

In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate CancerSemantic proximity Read ↗

Small Molecules Targeting the Disordered Transactivation Domain of the Androgen Receptor Induce the Formation of Collapsed Helical StatesSemantic proximity Read ↗

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsSemantic proximity Read ↗

Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.